Biovica, a Swedish biotech company founded in 2009, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome. Our initial focus is breast cancer, where approximately 1600 new cases are diagnosed every day in the EU and US alone. By collaborating with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies, we actively promote the growing drive towards personalized medicine. Improved patient survival plus lower healthcare costs are two anticipated and welcome outcomes.
Biovica’s clinical validation plan is supported by The European Commission and has been selected to receive funding in the Horizon 2020 phase 2 program.